Exhibit 99.1
PetMeds® Announces Second Quarter Financial Results

Delray Beach, Florida, November 10, 2026, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its second quarter ended September 30, 2026. 

Quarterly Highlights
•For the second quarter ended September 30, 2026, net sales were $35.8 million compared to $44.4 million for the prior year period, a decrease of 19.4%, primarily driven by a decline in prescription medication sales and higher consumer promotional usage.
•Net loss for the quarter ended September 30, 2026, was $6.4 million, or $(0.31) per diluted share, compared to a net loss of $8.5 million, or $(0.41) per diluted share, for the prior year period. The decrease in net loss was primarily driven by lower general and administrative expenses and advertising expenses. These favorable factors were partially offset by lower gross profit primarily driven by unfavorable product mix shift and lower manufacturer rebates as a percentage of sales, partially offset by lower net freight costs per order.
•Adjusted EBITDA1 was $(3.6) million compared to $(2.3) million in the prior year period.

“We have stabilized the operations of the business and our focus now is on transforming our core direct-to-consumer pharmacy business and making PetMeds a leaner, more profitable company at the size we are today,” said Jeff Willard, Chief Executive Officer and President of PetMeds. “We are already making progress: this quarter we cut our cost to acquire a new customer by 32% from a year ago. Next, we are repositioning the brand so pet parents know exactly why to choose PetMeds, making our marketing work harder, making our website easier to buy from, and keeping more of the customers we win. Every one of these steps is built to create a profitable PetMeds that can grow again.”

Earnings Webcast
PetMeds will host a webcast reviewing financial results for the second quarter ended September 30, 2026 at 4:30pm Eastern Time today. The webcast can be accessed at the “News & Events” section of the Company’s investor relations website at https://investors.petmeds.com/News--Events/events-and-presentations/default.aspx or directly here.
About PetMed Express, Inc.

Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PetMeds family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com

Forward Looking Statement

This press release may contain “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K for the year ended March 31, 2026, filed on June 2, 2026. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.
1 Adjusted EBITDA is a non-GAAP financial measure. See “Non-GAAP Financial Measures” for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measures.



Investor Contact:
ICR, LLC
Reed Anderson
(646) 277-1260
investor@petmeds.com



PETMED EXPRESS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except for share and per share amounts)
September 30,
2026		March 31,
2026
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents$11,418 $21,412 
Accounts receivable, less allowance for credit losses of $0 and $25, respectively
1,373 1,908 
Inventories6,303 13,608 
Prepaid expenses and other current assets6,187 6,378 
Prepaid income taxes62 258 
Total current assets25,343 43,564 
Noncurrent assets:
Property and equipment, net23,472 26,326 
Intangible and other assets, net10,310 10,789 
Operating lease right-of-use assets278 512 
Total noncurrent assets34,060 37,627 
Total assets$59,403 $81,191 
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable$15,258 $20,906 
Sales tax payable18,927 22,261 
Accrued expenses and other current liabilities7,302 7,665 
Current operating lease liabilities291 493 
Deferred revenue588 689 
Income taxes payable— 20 
Total current liabilities42,366 52,034 
Deferred tax liabilities, net175 175 
Operating lease liabilities, net of current lease liabilities— 42 
Total liabilities42,541 52,251 
Shareholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized:
    Convertible preferred stock, $0.001 par value, with a liquidation preference of $4 per share, 250,000 shares authorized; 2,500 and 2,500 convertible shares issued and outstanding, respectively
9 9 
    Series A Junior Participating Preferred Stock, $0.001 par value, 100,000 shares authorized; no shares issued or outstanding
— — 
   Common stock, $.001 par value, 40,000,000 shares authorized; 22,131,508 and 21,385,638 shares issued and outstanding, respectively
22 21 
Additional paid-in capital20,147 19,647 
Retained earnings(3,316)9,263 
Total shareholders' equity16,862 28,940 
Total liabilities and shareholders' equity$59,403 $81,191 


PETMED EXPRESS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except for share and per share amounts) (Unaudited)

Three Months Ended September 30,Six Months Ended
September 30,

2026202520262025
Net sales$35,770 $44,364 $76,785 $95,544 
Cost of sales25,967 31,949 55,649 68,726 
Gross profit9,803 12,415 21,136 26,818 
Operating expenses:


General and administrative11,968 14,176 23,165 27,124 
Advertising2,072 4,341 6,292 10,387 
Depreciation and amortization2,182 2,278 4,330 4,561 
Impairment of goodwill and intangible assets— — — 27,258 
Total operating expenses16,222 20,795 33,787 69,330 
Loss from operations(6,419)(8,380)(12,651)(42,512)
Other income:
Interest (expense) income, net(195)(326)(533)(524)
Other, net194 195 632 382 
Total other (expense) income(1)(131)99 (142)
Loss before provision for income taxes(6,420)(8,511)(12,552)(42,654)
Provision for income taxes14 9 27 18 
Net loss$(6,434)$(8,520)$(12,579)$(42,672)
Basic and diluted net loss per share$(0.31)$(0.41)$(0.60)$(2.05)
Basic and diluted weighted-average common shares outstanding21,072,155 20,889,124 21,059,843 20,822,270 


PETMED EXPRESS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands) (Unaudited)

Six Months Ended
September 30,
20262025
Cash flows from operating activities:
Net loss$(12,579)$(42,672)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization4,330 4,561 
Impairment of goodwill and intangible assets— 27,258 
Share-based compensation524 839 
Bad debt (recovery) expense— 6 
(Increase) decrease in operating assets and increase (decrease) in operating liabilities:
Accounts receivable535 346 
Inventories7,305 1,437 
Prepaid income taxes196 36 
Prepaid expenses and other current assets191 (1,031)
Operating lease right-of-use assets234 225 
Accounts payable(5,648)(4,445)
Sales tax payable(3,334)416 
Accrued expenses and other current liabilities(133)(23)
Lease liabilities(244)(228)
Deferred revenue(101)(1,090)
Income taxes payable(20)(80)
Net cash used in operating activities(8,744)(14,445)
Cash flows from investing activities:
Purchases of property and equipment(1,227)(3,916)
Net cash used in investing activities(1,227)(3,916)
Cash flows from financing activities:
Dividends paid— (23)
Cash paid for tax withholding on net settlement of restricted stock(23)(238)
Net cash used in financing activities(23)(261)
Net decrease in cash and cash equivalents(9,994)(18,622)
Cash and cash equivalents, at beginning of period21,412 54,720 
Cash and cash equivalents, at end of period$11,418 $36,098 
Supplemental disclosure of cash flow information:
Cash paid for income taxes, net of refunds$(137)$66 
Dividends payable in accrued expenses and other current liabilities$— $1 
Non-cash investing activity for property and equipment additions
$(230)$(854)


Non-GAAP Financial Measures
To provide investors and the market with additional information regarding our financial results, we have disclosed (see below) adjusted EBITDA, a non-GAAP financial measure that we calculate as net income excluding share-based compensation expense (benefit), depreciation and amortization; income tax provision, interest income (expense), and certain other non-operational expenses. We have provided reconciliations below of net (loss) income to adjusted EBITDA, the most directly comparable GAAP financial measures.
We have included adjusted EBITDA, herein, because it is a key measure used by our management and Board of Directors to evaluate our operating performance, generate future operating plans, and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and other expenses. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors.
We believe it is useful to exclude non-cash charges, such as share-based compensation expense (benefit) and depreciation and amortization from our adjusted EBITDA because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude income tax provision and interest income (expense), as neither are components of our core business operations. We also believe that it is useful to exclude other non-operational expenses, employee severance, impairment of goodwill and intangible assets, and interest expense relating to an estimated unremitted prior sales tax accrual as these items are not indicative of our ongoing operations. Adjusted EBITDA has limitations as a financial measure, and these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:
•Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future and adjusted EBITDA does not reflect capital expenditure requirements for such replacements or for new capital expenditures;
•Adjusted EBITDA does not reflect net share-based compensation. Share-based compensation has been, and will continue to be for the foreseeable future, a material recurring expense in our business and an important part of our compensation strategy;
•Adjusted EBITDA does not reflect interest income (expense), net; or changes in, or cash requirements for, our working capital;
•Adjusted EBITDA does not reflect transaction related costs and other items which are either not representative of our underlying operations or are incremental costs that result from an actual or planned transaction and include litigation matters, integration consulting fees, internal salaries and wages (to the extent the individuals are assigned full-time to integration and transformation activities) and certain costs related to integrating and converging IT systems;
•Adjusted EBITDA does not reflect certain non-operating expenses including the employee severance which reduces cash available to us;
•Adjusted EBITDA does not reflect certain non-operating expenses (income) including sales tax expense (income) relating to recording a liability for sales tax we did not collect from our customers;
•Other companies, including companies in our industry, may calculate adjusted EBITDA differently, which reduces the measures usefulness as comparative measures.
Because of these and other limitations, Adjusted EBITDA should only be considered as supplemental to, and alongside with other GAAP based financial performance measures, including various cash flow metrics, net income, net margin, and our other GAAP results.


The following table presents a reconciliation of net loss, the most directly comparable GAAP measure to Adjusted EBITDA for each of the periods indicated:
Reconciliation of Unaudited Non-GAAP Measures
PetMed Express, Inc.
Three Months Ended
Increase (Decrease)
($ in thousands, except percentages)September 30, 2026September 30, 2025
$
%
Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA:
Net loss$(6,434)$(8,520)$2,086 24 %
Add (subtract):
Share-based Compensation Expense326 248 78 31 %
Income Taxes14 9 5 56 %
Depreciation and Amortization2,182 2,278 (96)(4)%
Interest Expense (Income), Net195 326 (131)(40)%
Employee Severance74 1,223 (1,149)(94)%
Professional Fees (1)
— 2,120 (2,120)(100)%
Adjusted EBITDA$(3,643)$(2,316)$(1,327)(57)%


Six Months Ended
Increase (Decrease)
($ in thousands, except percentages)September 30, 2026September 30, 2025$
Change		%
Change
Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA:
Net loss$(12,579)$(42,672)$30,093 71 %
Add (subtract):
Share-based Compensation Expense524 839 (315)(38)%
Income Taxes27 18 9 50 %
Depreciation and Amortization4,330 4,561 (231)(5)%
Interest Expense (Income), Net533 524 9 2 %
Employee Severance74 1,319 (1,245)(94)%
Professional Fees (1)
— 3,141 (3,141)(100)%
Impairment of goodwill and intangible assets
— 27,258 (27,258)(100)%
Adjusted EBITDA$(7,091)$(5,012)$(2,079)(41)%

(1) Consists of professional fees related to the completed Audit Committee investigation as previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2025.